AU2013300106B2 - Novel pyrrolopyrimidine compounds as inhibitors of protein kinases - Google Patents

Novel pyrrolopyrimidine compounds as inhibitors of protein kinases Download PDF

Info

Publication number
AU2013300106B2
AU2013300106B2 AU2013300106A AU2013300106A AU2013300106B2 AU 2013300106 B2 AU2013300106 B2 AU 2013300106B2 AU 2013300106 A AU2013300106 A AU 2013300106A AU 2013300106 A AU2013300106 A AU 2013300106A AU 2013300106 B2 AU2013300106 B2 AU 2013300106B2
Authority
AU
Australia
Prior art keywords
alkyl
hydrogen
certain instances
compound
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013300106A
Other languages
English (en)
Other versions
AU2013300106A1 (en
Inventor
Long Mao
Xiaobo Wang
Biao Xi
Xiao Xu
Li Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acea Biosciences Inc
Original Assignee
Acea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/843,554 external-priority patent/US9034885B2/en
Application filed by Acea Biosciences Inc filed Critical Acea Biosciences Inc
Publication of AU2013300106A1 publication Critical patent/AU2013300106A1/en
Application granted granted Critical
Publication of AU2013300106B2 publication Critical patent/AU2013300106B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
AU2013300106A 2012-08-06 2013-07-11 Novel pyrrolopyrimidine compounds as inhibitors of protein kinases Active AU2013300106B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261680231P 2012-08-06 2012-08-06
US61/680,231 2012-08-06
US13/843,554 US9034885B2 (en) 2012-01-13 2013-03-15 EGFR modulators and uses thereof
US13/843,554 2013-03-15
US201361814147P 2013-04-19 2013-04-19
US61/814,147 2013-04-19
US13/917,514 2013-06-13
US13/917,514 US8685988B2 (en) 2012-08-06 2013-06-13 EGFR modulators and uses thereof
PCT/US2013/050163 WO2014025486A1 (en) 2012-08-06 2013-07-11 Novel pyrrolopyrimidine compounds as inhibitors of protein kinases

Publications (2)

Publication Number Publication Date
AU2013300106A1 AU2013300106A1 (en) 2015-02-19
AU2013300106B2 true AU2013300106B2 (en) 2017-11-30

Family

ID=50068479

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013300106A Active AU2013300106B2 (en) 2012-08-06 2013-07-11 Novel pyrrolopyrimidine compounds as inhibitors of protein kinases

Country Status (22)

Country Link
EP (2) EP3170825B1 (enExample)
JP (2) JP6215938B2 (enExample)
KR (1) KR102181365B1 (enExample)
CN (2) CN107266453B (enExample)
AU (1) AU2013300106B2 (enExample)
BR (1) BR112015002709B1 (enExample)
CA (1) CA2881275C (enExample)
CY (1) CY1120844T1 (enExample)
DK (1) DK2880035T3 (enExample)
ES (2) ES2733576T3 (enExample)
HR (1) HRP20170311T1 (enExample)
HU (1) HUE031955T2 (enExample)
IN (1) IN2015DN00914A (enExample)
LT (1) LT2880035T (enExample)
MX (1) MX361992B (enExample)
NZ (1) NZ629807A (enExample)
PT (1) PT2880035T (enExample)
RU (2) RU2645672C2 (enExample)
SG (1) SG11201500872SA (enExample)
SM (1) SMT201700136T1 (enExample)
WO (1) WO2014025486A1 (enExample)
ZA (2) ZA201500762B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11007197B2 (en) 2012-08-06 2021-05-18 ACEA Therapeutics, Inc. EGFR modulators and uses thereof
US11498922B2 (en) 2017-04-07 2022-11-15 ACEA Therapeutics, Inc. Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6105578B2 (ja) 2011-07-21 2017-03-29 トレロ ファーマシューティカルズ， インコーポレイテッド 複素環式プロテインキナーゼ阻害剤
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
CN110194748A (zh) 2012-01-13 2019-09-03 艾森生物科学公司 杂环化合物及其作为抗癌药的用途
CN105188704B (zh) 2013-01-16 2017-09-19 西格诺药品有限公司 被取代的吡咯并嘧啶化合物、其组合物和使用其的治疗方法
US10202356B2 (en) * 2013-03-14 2019-02-12 Tolero Pharmaceuticals, Inc. JAK2 and ALK2 inhibitors and methods for their use
EP3019496B1 (en) * 2013-07-11 2019-09-11 ACEA Therapeutics, Inc. Pyrimidine derivatives as kinase inhibitors
WO2015127234A1 (en) * 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
CA2955009A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EP3256475A4 (en) 2015-02-13 2019-02-13 Dana-Farber Cancer Institute, Inc. LRRK2 INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
JP2018104290A (ja) * 2015-04-28 2018-07-05 アステラス製薬株式会社 ピラジンカルボキサミド化合物を有効成分とする医薬組成物
CN107973791B (zh) * 2015-04-29 2020-04-07 南京圣和药业股份有限公司 稠环或三环芳基嘧啶化合物用作激酶抑制剂
WO2017011720A1 (en) * 2015-07-16 2017-01-19 Signal Pharmaceuticals, Llc Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
US10533011B2 (en) * 2015-10-09 2020-01-14 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
CN105646496B (zh) * 2016-01-20 2018-07-20 华侨大学 一种7H-吡咯并[2,3-d]嘧啶衍生物、其合成方法及应用
CN107540661A (zh) * 2016-06-24 2018-01-05 正大天晴药业集团股份有限公司 作为egfr抑制剂的苯胺嘧啶化合物的结晶
CN107663208B (zh) * 2016-07-27 2021-10-15 南京圣和药业股份有限公司 一种新型egfr激酶抑制剂的药用盐及其制备方法与用途
CN107663207B (zh) * 2016-07-27 2021-07-30 南京圣和药业股份有限公司 一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法
CN107955019B (zh) * 2016-10-17 2021-09-14 广东众生药业股份有限公司 一种egfr抑制剂的盐型、晶型及其制备方法
CN106749266B (zh) * 2016-11-14 2019-01-22 山东大学 吡咯并[2,3-d]嘧啶类化合物的高效制备方法
CN108299419B (zh) * 2017-01-11 2022-04-26 南京圣和药业股份有限公司 一种新型egfr激酶抑制剂的几种新晶型及其制备方法
US11608334B2 (en) 2017-02-08 2023-03-21 The National Institutes of Pharmaceutical R&D Co., Ltd. Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof
CN109422751B (zh) * 2017-09-03 2022-04-22 上海美志医药科技有限公司 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
US11709155B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
US12180581B2 (en) 2017-09-18 2024-12-31 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
US11709156B2 (en) 2017-09-18 2023-07-25 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved analytical analysis
US12181452B2 (en) 2017-09-18 2024-12-31 Waters Technologies Corporation Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes
KR102577241B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
PE20201146A1 (es) 2017-12-28 2020-10-26 Dae Woong Pharma Derivado de oxi-fluoropiperidina como inhibidor de quinasa
KR102577242B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
CN112236139A (zh) 2018-04-13 2021-01-15 大日本住友制药肿瘤公司 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
CN108530450B (zh) * 2018-05-03 2021-03-30 赖建智 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用
EP3826684A4 (en) 2018-07-26 2022-04-06 Sumitomo Dainippon Pharma Oncology, Inc. METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME
EP3613738A1 (en) * 2018-08-23 2020-02-26 Lead Discovery Center GmbH 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer
JP7662528B2 (ja) 2019-02-12 2025-04-15 スミトモ ファーマ アメリカ， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
CN110407840A (zh) * 2019-08-15 2019-11-05 重庆化工职业学院 一种艾维替尼的制备方法
JP7473642B2 (ja) * 2019-11-13 2024-04-23 ジャージアン・ロングチャーム・バイオ－テック・ファーマ・カンパニー・リミテッド Ｂｔｋ阻害剤としてのピロロピリミジン系化合物およびその使用
US11918936B2 (en) 2020-01-17 2024-03-05 Waters Technologies Corporation Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding
WO2021147952A1 (zh) * 2020-01-21 2021-07-29 江苏先声药业有限公司 嘧啶并吡咯类化合物
CN111848631B (zh) * 2020-08-28 2022-04-19 四川大学华西医院 一种靶向EGFR突变的吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途
EP4217730B1 (en) 2020-09-24 2025-08-20 Waters Technologies Corporation Chromatographic hardware improvements for the separation of reactive molecules
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
EP4279486A4 (en) * 2021-01-11 2024-12-11 Guangzhou Salustier Biosciences Co., Ltd. 2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
CN114957248B (zh) * 2022-05-09 2023-12-29 南开大学 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用
CN115611989B (zh) * 2022-10-09 2023-08-01 武汉理工大学 机械活化淀粉衍生物抑制剂的优化制备方法及应用
WO2024092047A1 (en) 2022-10-26 2024-05-02 Sorrento Therapeutics, Inc. Administration of pyrrolopyrimidine-based kinase inhibitors for treatment of psoriasis
EP4611753A1 (en) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129053A2 (en) * 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
WO2011079231A1 (en) * 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563905A (en) 1992-09-24 1996-10-08 Hughes Aircraft Company Network communication system having time-sliced protocol
US7560269B2 (en) 2002-12-20 2009-07-14 Acea Biosciences, Inc. Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays
US7470533B2 (en) 2002-12-20 2008-12-30 Acea Biosciences Impedance based devices and methods for use in assays
US7732127B2 (en) 2002-12-20 2010-06-08 Acea Biosciences, Inc. Dynamic monitoring of cell adhesion and spreading using the RT-CES system
ATE448482T1 (de) 2002-07-20 2009-11-15 Acea Biosciences Inc Vorrichtungen auf impedanzbasis sowie verfahren zur verwendung in assays
US7468255B2 (en) 2002-12-20 2008-12-23 Acea Biosciences Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology
EP1692258A4 (en) 2003-11-12 2007-03-21 Xiao Xu REAL-TIME ELECTRONIC CELL DETECTION SYSTEMS FOR CELL-BASED TESTS
PL1928872T3 (pl) * 2005-09-21 2012-08-31 4Sc Ag Nowe sulfonylopirole jako inhibitory HDAC

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010129053A2 (en) * 2009-05-05 2010-11-11 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
WO2011079231A1 (en) * 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11007197B2 (en) 2012-08-06 2021-05-18 ACEA Therapeutics, Inc. EGFR modulators and uses thereof
US11498922B2 (en) 2017-04-07 2022-11-15 ACEA Therapeutics, Inc. Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide

Also Published As

Publication number Publication date
EP2880035B9 (en) 2017-05-17
NZ629807A (en) 2017-04-28
SG11201500872SA (en) 2015-03-30
SMT201700136T1 (it) 2017-05-08
KR102181365B1 (ko) 2020-11-23
EP3170825A1 (en) 2017-05-24
HK1210471A1 (en) 2016-04-22
DK2880035T3 (en) 2017-03-06
KR20150068949A (ko) 2015-06-22
CA2881275C (en) 2020-10-20
BR112015002709A2 (pt) 2017-07-04
JP6215938B2 (ja) 2017-10-18
ES2618007T3 (es) 2017-06-20
EP2880035A1 (en) 2015-06-10
CN103748096B (zh) 2017-10-20
HRP20170311T1 (hr) 2017-04-21
JP2017061581A (ja) 2017-03-30
BR112015002709B1 (pt) 2022-09-20
CN103748096A (zh) 2014-04-23
IN2015DN00914A (enExample) 2015-06-12
LT2880035T (lt) 2017-03-27
EP2880035B1 (en) 2016-12-07
JP2015524468A (ja) 2015-08-24
ZA201500762B (en) 2021-09-29
WO2014025486A1 (en) 2014-02-13
AU2013300106A1 (en) 2015-02-19
PT2880035T (pt) 2017-03-10
HUE031955T2 (en) 2017-08-28
EP3170825B1 (en) 2019-04-10
MX2015001715A (es) 2015-07-06
CA2881275A1 (en) 2014-02-13
CN107266453B (zh) 2020-02-07
ES2733576T3 (es) 2019-12-02
RU2645672C2 (ru) 2018-02-27
RU2015107831A (ru) 2016-09-27
CN107266453A (zh) 2017-10-20
RU2018104702A (ru) 2019-02-22
CY1120844T1 (el) 2019-12-11
MX361992B (es) 2018-12-19
ZA201600648B (en) 2021-09-29

Similar Documents

Publication Publication Date Title
AU2013300106B2 (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
US10596174B2 (en) Pyrrolopyrimidine compounds as inhibitors of protein kinases
US11007197B2 (en) EGFR modulators and uses thereof
EP3392245A1 (en) Novel egfr and alk dual inhibitor
US9586965B2 (en) Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
CN104844566A (zh) 一种新型结构的激酶抑制剂
HK1238243A1 (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
HK1238243B (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
HK1210471B (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)